Epratuzumab

Drug Profile

Epratuzumab

Alternative Names: AMG 412; Epratucyn; hCD22; Humanised monoclonal antibody LL2; Humanized anti-CD22 monoclonal antibody IgG1; IMMU 103; IMMU LL2; LymphoCide

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Immunomedics
  • Developer Charite of Berlin; Immunomedics; National Cancer Institute (USA); UCB
  • Class Monoclonal antibodies
  • Mechanism of Action CD19 antigen modulators; CD22 antigen modulators; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia; Systemic lupus erythematosus
  • Phase II Non-Hodgkin's lymphoma
  • Discontinued Cachexia

Most Recent Events

  • 06 Dec 2016 Safety and efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 26 Feb 2016 UCB terminates its worldwide licence for epratuzumab
  • 01 Feb 2016 UCB Pharma completes the phase III EMBODY 4 trial in Systemic lupus erythematosus in USA, Australia, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Israel, Italy, South Korea, Lithuania, Mexico, Poland, Romania, Russia, South Africa, Spain, Taiwan, Ukraine and United Kingdom (NCT01408576)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top